Arla Foods Ingredients has launched a new whey protein hydrolysate with a better taste profile than comparable ingredients for peptide-based medical nutrition.
The highly hydrolysed whey protein ingredient Lacprodan DI-3092 allows 10g of high-quality single-source protein to be packed into 100 ml, significantly higher than the market standard of 6-7g per 100 ml.
It has also been designed to taste great with minimal bitterness, helping overcome a key challenge in medical nutrition.
Whey protein hydrolysates are produced through an enzymatic process, breaking protein into peptides. Sometimes described as “pre-digested”, they are a valuable solution for the nutritional needs of patients with impaired gastrointestinal function or nutrient absorption.
However, peptide-based products are also known for their unappealing bitter taste. This has been a serious problem, given the impact of taste and texture on compliance with medical nutrition.
Many patients reported that medical drinks have an unpleasant texture and taste. In a recent study, half of those recommended medical nutrition plans were not completed or did not take the total dosage.
“Whey protein hydrolysates are essential for peptide-based medical nutrition, but three key challenges are in the category. The first is to improve taste and texture, which is important to ensure patient compliance,” said Mads Dyrvig, Head of Sales Development, Specialised Nutrition at Arla Foods Ingredients.
“The second is to go higher in protein, and the third is to use a high-quality protein source. Lacprodan DI-3092 – our best-tasting whey protein hydrolysate yet – overcomes all three challenges.”
Arla Foods Ingredients has created two new prototypes to showcase the new product: a ready-to-drink beverage and a ready-to-mix powder. Both the 200Kcal recipes contain 10g protein/100 ml and offer a very mild taste and low viscosity.
Lacprodan DI-3092 offers high hydrolysis (16 to 22 percent) and low lactose content. It is also UHT-stable, making it suitable for direct and indirect heat treatment.
More news here
